Amgen is making a significant strategic push into the chronic weight management market, initiating six large-scale Phase 3 studies for its GLP-1 drug, MariTide.
Filing excerpt
In March 2025, we announced the initiation of two global Phase 3 studies to evaluate MariTide, a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR), in chronic weight management...
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10kproductLaunchGet every 10-K signal for Amgen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/5b97dd23-1577-451d-ba63-259ac8d4c5ec returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.
{
"signal_id": "5b97dd23-1577-451d-ba63-259ac8d4c5ec",
"signal_type": "sec-10k",
"signal_subtype": "productLaunch",
"detected_at": "2026-02-17T06:28:58.463+00:00",
"company": {
"name": "Amgen",
"domain": "amgen.com"
},
"data": {
"detail": "Amgen is making a significant strategic push into the chronic weight management market, initiating six large-scale Phase 3 studies for its GLP-1 drug, MariTide. This indicates substantial budget allocation and resource investment towards clinical development, data analysis, and future commercialization.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Amgen running six global Phase 3 studies for new weight-loss drug, MariTide",
"excerpts": "In March 2025, we announced the initiation of two global Phase 3 studies to evaluate MariTide, a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR), in chronic weight management...",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm",
"filing_date": "2026-02-13",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"technologies_mentioned": [
"GLP-1"
]
}
}
curl https://signals.autobound.ai/v1/signals/5b97dd23-1577-451d-ba63-259ac8d4c5ec \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.